SANTANDER UK PLC — Board/Management Information 2018

May 31, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8445P

Santander UK Plc

31 May 2018

SANTANDER UK GROUP HOLDINGS PLC AND SANTANDER UK PLC (together "Santander UK")

31 May 2018

Santander UK announces the appointment of Julie Chakraverty as an Independent Non-executive Director of Santander UK on 11 June 2018 and that Alain Dromer will be stepping down from the Board of Santander UK on 31 August 2018 after five years' service.

BIOGRAPHICAL DETAILS

Julie Chakraverty is the Founder and Chief Executive of Rungway Limited, a business-to-business culture and talent platform company.  She was a Non-Executive Director of Standard Life Aberdeen plc, having been a Non-Executive Director of Aberdeen Asset Management plc since May 2011 and Senior Independent Director since October 2016, until her retirement from the Board at their Annual General Meeting earlier this week.  She chaired their Risk Committee and Innovation Committee.

Previously, Julie served on the Boards of MS Amlin plc (where she chaired their Remuneration Committee), Spirit Pub Company Limited and Paternoster Limited.  Her executive career was spent with UBS, where she held a number of global leadership positions, and JP Morgan.

Julie brings extensive financial services experience, digital and innovation knowledge, proven business leadership and entrepreneurial experience and a background in risk management.

There is no other information to be disclosed under paragraph 9.6.13 of the Listing Rules.

For media enquiries, please contact:

Andy Smith, Head of Media Relations

Tel: +44 (0) 20 7756 4212

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOALIFSAETILVIT